Abstract. Inflammation has been widely recognized as a contributor to cancer progression and several inflammatory markers have been reported as associated with the clinical outcomes in patients with various types of cancer. Recently, a novel inflammatory marker, the systemic inflammatory score (SIS), which is based on a combination of the lymphocyte-to-monocyte ratio (LMR) and the serum albumin concentration has been reported as a useful prognostic marker. The aim of the present study was to assess the prognostic value of the SIS in patients with unresectable metastatic colorectal cancer (mCRC). The retrospective cohort study included 160 patients who underwent combination chemotherapy for unresectable mCRC between January 2008 and December 2016. The SIS was used to classify the patients into three groups based on their LMR and the serum albumin concentration. Patients with high-LMR and high serum albumin level were given a score of 0; patients with low-LMR or low serum albumin level were given a score of 1; patients with low-LMR and low serum albumin level were given a score of 2. There were significant differences in the overall survival among the three SIS groups and the SIS was an independent prognostic factor for the overall survival. Although the SIS was significantly associated with the overall survival rate even when using the original cut-off values, the SIS according to the new cut-off values had a more accurate prognostic value. The present study determined that the SIS was a useful biomarker for predicting the survival outcomes in patients with unresectable mCRC, although the optimum cut-off value of the SIS according to the patients' background needs to be examined in further studies.
Introduction
Inflammation is known to contribute to cancer progression (1, 2) , and several inflammatory markers, such as the neutrophil-to-lymphocyte ratio (NLR), the lymphocyte-to-monocyte ratio (LMR) and the Glasgow prognostic score (GPS) have been reported to be associated with clinical outcomes in patients with various types of cancer, including colorectal cancer (3) (4) (5) (6) (7) (8) . Recently, a new inflammatory marker, the systemic inflammatory score (SIS), based on the combination of the LMR and the serum albumin concentration has been reported to be a useful prognostic marker in patients with clear-cell renal cell carcinoma, colorectal cancer and oral cavity squamous cell carcinoma (9) (10) (11) .
However, there are only a few reports on the SIS, and the prognostic value of the SIS in patients with unresectable metastatic colorectal cancer (mCRC) remains unclear. In addition, the optimum cut-off value may change depending on the type of cancer and stage and merits further study.
This study aimed to evaluate the prognostic value of the SIS and to determine its optimum cut-off value in patients with unresectable mCRC who underwent chemotherapy.
Materials and methods
Patients. This retrospective cohort study included 160 patients who underwent combination chemotherapy for unresectable mCRC at the Department of Surgical Oncology of Osaka City University (Osaka, Japan) between January 2008 and December 2016.
Methods. Blood samples were collected within one week prior to the initiation of chemotherapy. We analyzed the differential white blood cell count using an XE-5000 hematology analyzer (Sysmex, Kobe, Japan) based on the manufacturer's protocol. The LMR was calculated by dividing the absolute number of circulating lymphocytes by the absolute number of circulating monocytes. We assessed the serum albumin concentrations by a chemiluminescent immunoassay (Wako, Osaka, Japan) according to the manufacturer's protocol. The SIS was defined according to the methods of a previous report (9) , using the The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer combination of the LMR and the serum albumin concentration: patients with LMR >4.44 and serum albumin level >4.0 g/dl were given a score of 0; patients with LMR ≤4.44 or serum albumin level ≤4.0 g/dl were given a score of 1; patients with LMR ≤4.4 and 4 serum albumin level ≤4.0 g/dl were given a score of 2. The location of the primary tumor was defined as follows. The oral side of the splenic flexure was termed 'the right side' and the anal side of splenic flexure was termed 'the left side'. Furthermore, we defined synchronous and metachronous metastases as follows. Synchronous metastases were defined as metastatic lesions that were already confirmed at the time of the diagnosis of the primary lesion; metachronous metastases were defined as metastatic lesions that developed after the excision of the primary tumor, regardless of the period.
Ethical considerations. All patients were informed of the investigational nature of this study and provided their written informed consent for the retrospective analysis of their data. Full ethical approval was granted by the Ethics Committee of Osaka City University (approval no. 926).
Statistical analysis. The significance of the correlations between the SIS and the clinicopathological characteristics were analyzed using the Chi-squared test. Survival curves were constructed using the Kaplan-Meier method and were compared using the log-rank test. A multivariate analysis was performed using a Cox proportional hazards model. All of the statistical analyses were performed using the SPSS software program (version 19.0; IBM, Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Patients' baseline characteristics. The characteristics of the 160 patients in the present study are summarized in Table I . The study population included 86 male patients and 74 female patients. The median age of the patients was 65 years (range: 18 to 89). According to the definition of the Eastern Cooperative Oncology Group performance status (PS), 140 patients were classified as having a PS of 0, 17 were classified as having a PS of 1, and 3 were classified as having a PS of 2. A total of 39 patients had primary tumors located on the right side, and 121 had primary tumors located on the left side. One hundred and seven patients had single-organ metastasis, and 53 multiple organs affected by metastases. All of the patients underwent combination chemotherapy with oxaliplatin, irinotecan plus 5-fluorouracil/leucovorin, or a prodrug of 5-fluorouracil as first-line chemotherapy. The regimens used for all of the patients in this study were considered to have the same efficacy (12) (13) (14) . Seventy-five patients received FOLFOX, 53 received CapeOX, 25 received FOLFIRI, and 7 SOX. A total of 103 patients underwent chemotherapy combined with molecular-targeted therapy.
The median follow-up period for the surviving patients was 21.8 months (range: 1.2 to 94.0 months). A total of 113 patients died during the follow-up period.
Correlations between the SIS and clinicopathological factors.
The correlations between the SIS and clinicopathological factors are shown in Table II . The SIS and clinicopathological factors did not differ to a statistically significant extent.
Prognostic significance of the SIS according to the original cut-off values defined in the previous report.
The median overall survival time was 31.6 months in those with a SIS of A log-rank test demonstrated significant differences in the overall survival among the three groups (P=0.0021). However, there were no significant differences in the overall survival between the patients with a SIS of 1 and those with a SIS of 2, although the overall survival rate tended to be worse in patients with a SIS of 2 than in those with a SIS of 1 (P=0.0810; Fig. 1 ).
Univariate and multivariate analyses of the risk factors for overall survival. In the univariate analysis, the PS, the location of the primary tumor, the RAS status and the SIS were associated with overall survival. Furthermore, a multivariate analysis demonstrated that gender, the location of the primary tumor and the SIS were independent prognostic factors for survival (Table III) . (Fig. 2) . The patients were classified into the high-LMR (n=120) and low-LMR (n=40) groups based on the new cut-off LMR. In the same way, the patients were classified into the high-ALB (n=60) and low-ALB (n=100) groups.
Prognostic value of the LMR and the serum albumin concentration.
The patients in the low-LMR group had a significantly worse overall survival rate in comparison to the patients in the high-LMR group (P<0.0001; Fig. 3A) . Similarly, the patients in the low-ALB group had significantly worse overall survival in comparison to the high-ALB group (P=0.0004; Fig. 3B ). 
Univariate analysis Multivariate analysis --------------------------------------------------------------------------------------------------------------------------------------------------Characteristic
Hazard Prognostic value of the SIS according to the new cut-off value derived in our data set. According to the new cut-off value (LMR: 2.96, serum albumin level: 4.0) as well as the original cut-off value, the SIS was significantly associated with the overall survival rates (P<0.0001; Fig. 4) . Furthermore, there were significant differences between the each subgroup.
Discussion
The results obtained in this study suggested that the SIS was significantly associated with the survival outcomes and may be useful as a prognostic biomarker in patients with unresectable mCRC. To our knowledge, this is the first study to assess the prognostic value of the SIS in patients with unresectable mCRC. Albumin is a protein synthesized in the liver. Under conditions of systemic inflammation, the ability to synthesize albumin decreases, resulting in hypoalbuminemia (15) . Therefore, a low serum albumin concentration is associated with ongoing systemic inflammation. Due to the fact that continuous systemic inflammation promotes cancer progression (1,2), hypoalbuminemia is associated with a poor survival (16) .
The LMR reflects the balance between the immune status of the host and the degree of tumor burden. Lymphocytes play a key role in anticancer immunity (1,17) , and a decreasing number of lymphocytes has been reported to be associated with a poor prognosis (18, 19) . In contrast, monocytes contribute to cancer progression (1, 20, 21) . Circulating monocytes differentiate into macrophages in the cancer microenvironment (22, 23) . Most macrophages in the cancer microenvironment have an M2-like phenotype and promote tumor growth, angiogenesis and metastasis (20, 24) . Thus an increasing number of monocytes has been reported to be associated with a poor prognosis (5, 18, 25) . For these reasons, a low LMR is associated with a poor prognosis. The serum albumin concentration and white blood cell count are inexpensive to measure and are routinely applied in clinical practice. The combination of these two inflammatory markers based on different mechanisms may enable a more accurate prognostic prediction.
Both the serum albumin concentration and the LMR, which are components of the SIS, are markers related to inflammation, but their severity is not always correlated with each other (11) . Therefore, the combination of these two markers enables a more detailed stratification. The SIS can be used to classify patients into three risk subgroups, whereas most inflammatory markers reported as prognostic markers in previous reports are only able to divide patients into two groups. The GPS as well as the SIS can classify patients into three risk subgroups. However, according to the GPS, most patients (80-90%) are classified into the low-risk group (10, 26, 27) , and the distribution of the GPS score is not well-balanced. In contrast, the distribution of the SIS score is relatively well-balanced. These results suggest that the SIS may have higher clinical utility than other inflammatory markers.
According to the original cut-off values defined in a previous report, the SIS was significantly associated with the survival. However, the optimum cut-off values derived in our dataset was different from those obtained in the previous report. As cancer progresses, the degree of inflammation caused by the response of the host to the cancer increases (3). In previous reports, the inflammatory markers tended to increase as the stage progressed (3, 10, 28) . Furthermore, even at the same stage, the degree of inflammation may vary depending on the type of cancer. The optimum cut-off values of the inflammatory markers used in previous reports differed by type of cancer, even at the same stage (29) (30) (31) . Therefore, it is necessary to reset the optimum cut-off value of the serum albumin concentration and the LMR, which is most closely associated with the prognosis, depending on the characteristics of the target, such as the cancer type and stage. The optimum cut-off value of the SIS needs to be examined in further studies, which include a large unified population of cancer types, stages and treatments. The same may be true of the cut-off for the GPS.
The AUC of the ROC curve for the LMR and the serum albumin concentration were relatively low, despite both markers having been reported to be useful prognostic markers in many previous reports (5, 6, 16) . We thought that the small number of cases was the reason for the low AUC. A large prospective study is therefore necessary to confirm the usefulness of the SIS as a prognostic marker.
In conclusion, the SIS is considered to be a useful biomarker for predicting the survival outcomes in patients with unresectable mCRC cancer who undergo chemotherapy, although the optimum cut-off value according to each patient's background needs to be examined in further studies. Patients with high SIS scores are expected to have a poor prognosis. Thus, an intensive chemotherapy regimen aiming at cytoreduction-as opposed to disease control-should be selected for patients with a high SIS score. The SIS may contribute to decisions regarding the choice of therapeutic strategies.
